Tiny Sugars in the Brain Disrupt Emotional Circuits, Fueling Depression
Table of Contents
A groundbreaking new study reveals a direct link between abnormal sugar modifications in the brain and the development of depression, offering potential avenues for more effective treatments. Affecting over 280 million people globally as of 2025, depression is a debilitating disorder, and this research from the Institute for Basic Science (IBS) identifies a novel molecular pathway contributing to its onset.
The Glycosylation Connection
Researchers led by C. Justin Lee and Lee Boyoung have pinpointed a critical role for brain O-glycosylation – the process by which sugar chains attach to proteins – in the manifestation of depressive behaviors. Specifically, chronic stress disrupts these sugar chains in the prefrontal cortex, triggering a cascade of events that ultimately lead to symptoms of depression.
The findings, published in Science Advances, challenge conventional understandings of depression, which largely focus on neurotransmitter imbalances like serotonin. While existing antidepressant drugs targeting neurotransmitters benefit only about half of patients and often come with unwanted side effects, this new research opens the door to therapies that address the root cause of the illness at a molecular level.
Unraveling the Molecular Mechanism
The team employed a multi-omics approach, utilizing high-resolution mass spectrometry to analyze O-glycan composition and protein alterations across nine distinct brain regions in mice exhibiting depression-like behaviors induced by chronic variable stress. This comprehensive analysis revealed a pronounced reduction in sialylation – the addition of sialic acid to sugar chains, which stabilizes proteins – and a corresponding downregulation of the enzyme St3gal1 in the prefrontal cortex.
Further investigation demonstrated that decreased St3gal1 destabilizes the sugar chain structures of crucial synaptic molecules, including neurexin 2 (NRXN2), a synaptic adhesion protein. This disruption impairs the function of inhibitory neurons, essential for maintaining balance in brain circuits. “In other words, small changes in sugar chains simultaneously disrupted both the connections and stability of neural circuits, ultimately collapsing the brain’s emotion-regulation system,” explained the researchers.
St3gal1: A Key Regulator of Mood
To confirm the direct link between St3gal1 and depressive behavior, the researchers manipulated St3gal1 expression in mice. Suppressing St3gal1 in normal mice induced depressive-like symptoms – including loss of motivation and heightened anxiety – even without exposure to stress. Conversely, increasing St3gal1 expression in stressed mice alleviated their depressive behaviors.
These results definitively identify decreased St3gal1 as a key molecular factor that directly induces and regulates depressive symptoms. Experiments showed that mice with suppressed St3gal1 exhibited increased latency to feed in a novel environment, reflecting heightened anxiety, and decreased sucrose preference, indicating anhedonia – the inability to experience pleasure. Restoring St3gal1 expression, however, significantly improved these behavioral deficits.
Implications for Future Therapies
“This study demonstrates that abnormal glycosylation in the brain is directly connected to the onset of depression,” said Research Fellow Boyoung Lee. “It provides an important foothold for identifying new diagnostic markers and therapeutic targets beyond neurotransmitters.”
Director C. Justin Lee added that this achievement could extend beyond depression therapy to other mental illnesses such as PTSD and schizophrenia, paving the way for broader therapeutic strategies. The research underscores the importance of exploring novel molecular pathways in the brain to address the limitations of current treatments and improve outcomes for the millions affected by depression worldwide.
More information:
Youngsuk Seo et al, Abnormal O-Glycan Sialylation in the mPFC Contributes to Depressive-like Behaviors in Male Mice, Science Advances (2025). DOI: 10.1126/sciadv.ady2733.
